About Intro
At Keros, our mission is to deliver significant clinical benefit to a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. With a focus on developing differentiated product candidates that are designed to alter TGF-β signaling, we aim to target the pathways critical for the growth, repair and maintenance of blood cells and a number of tissues, including bone, skeletal muscle, adipose and heart tissue. We believe our product candidates have the potential to unlock the full therapeutic benefits of modulating the TGF-β superfamily and provide disease-modifying benefit to patients.
Cibotercept is currently being developed for the treatment of pulmonary arterial hypertension.
KER-065 is being developed for the treatment of neuromuscular diseases.
Elritercept is being developed to treat ineffective hematopoiesis in both myelodysplastic syndromes and myelofibrosis.
Furthermore, we are leveraging our expertise in TGF-β biology to fuel our research engine with the goal of bringing additional innovative treatment options to patients with diseases of high unmet medical need.
